Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06247813

Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain

The goal of this study is to use pain-specific urine biomarkers to evaluate how daily nutritional supplementation with biomarker guided formulas effect, quality of life and urinary biomarker scores in chronic pain patients. Assessing the effect of biomarker guided supplementation on pain specific biomarkers through changes in urinary biomarker scores may solidify the necessity for identifying deficiencies to create an individualized treatment plan for pain patients. This study aims to evaluate the effect of biomarker-guided supplementation on the three categories of urinary biomarkers using targeted ingredients specifically designed for oxidative stress, inflammation, and nerve health. This study provides subjects with one of three nutritional supplement formulas based on their specific urinary biomarker test results and assesses changes in their urinary biomarker levels and their quality of life as it relates to their pain over a 3-month period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Ethos Research and Development

Newport, Kentucky, 41071, United States

Location status: Recruiting

Location contact

Brianna Krause, MS

CONTACT

[email protected]

352-502-3854

Joshua Gunn, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Previously submitted a urinary biomarker sample and agreed to be contacted for research.
  • Be seeking treatment for chronic pain as defined as symptoms persisting for ≥ 3 months.
  • Be able to take oral medication and/or be willing to adhere to the supplement regimen.

Exclusion criteria

  • Diagnosis of bacterial or viral infection during or 3 months prior to the study.
  • Severe or untreated psychiatric disturbance and/or any psychiatric disorder that required hospitalization in the year prior to the screening visit.
  • A history of cancer within 5 years prior to screening visit.
  • Be pregnant or breast-feeding or have plans to become pregnant at any time during the study
  • Participant has a known sensitivity or allergy to any of the ingredients in the study products.
  • Participant has any dietary restriction that prevents the participant from consuming any of the ingredients in the study products.

Treatment and study plan

Inflammation Support Formula

Dietary Supplement

Turmeric Extract (400mg), Bioperine (Black pepper, 10mg), Ashwagandha (500mg), and Olive Leaf Extract (250mg).

Nerve Health Formula

Dietary Supplement

Hydroxocobalamin (Vitamin B12, 1000mcg), Pyridoxal-5-Phosphate (Vitamin B6, 50mg), LMethylfolate (400mcg) and Trimethyl Glycine (Betaine, 750mg).

Redox Support Formula

Dietary Supplement

N-Acetyl-L-Cysteine (500mg), CoQ10 (250mg), Acetyl-L-Carnitine (200mg), Alpha Lipoic Acid (200mg), Benfotiamine (300mg), Selenium (250mcg), Riboflavin (50mg), Zinc (15mg) and Copper (1.8mg).

Primary outcomes

  1. Quantitative urine biomarker levels.

    Time frame: 1 and 3 months of supplementation.

    Quantitative urine biomarker levels after 1 and 3 months of supplementation.

  2. Quality-of-life measures.

    Time frame: 1 month of supplementation, 3 months and at 3 month follow up.

    Summary scores of quality-of-life measures, patient reported outcome measurement information system 29 (PROMIS-29); assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. For overall scoring of the test (i.e., adding each response) a higher score equals more of the concept being measured (e.g., more Fatigue, more Physical Function), meaning a worse outcome.

  3. Quality-of-life measures.

    Time frame: 1 month of supplementation, 3 months and at 3 month follow up.

    Summary scores of quality-of-life measures, Short Form- 36 (SF-36); The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. Coding of each item varies across the measure however all items are scored so that a high score defines a more favorable health state.

Secondary outcomes

  1. Visual Analog Scale pain scores

    Time frame: 1 month, 2 months, 3 months and at 3 month follow up.

    Visual Analog Scale (VAS) pain scores are asked with 4 questions, current pain, worst pain, least pain and average pain since the subjects last visit. The scale is 0 to 10 where 0 is "no pain" and 10 is "worst imaginable pain", 10 would indicate a worse outcome.

  2. Depression symptoms.

    Time frame: 1 month, 2 months, 3 months and at 3 month follow up.

    Percentage of subjects with a decrease in depression symptoms.

  3. Anxiety symptoms.

    Time frame: 1 month, 2 months, 3 months and at 3 month follow up.

    Percentage of subjects with a decrease in anxiety symptoms.

  4. Sleep quality score

    Time frame: 1 month, 2 months, 3 months and at 3 month follow up.

    Sleep quality (Pittsburg Sleep Quality Index (PSQI)) score (and subscale scores). The PSQI is a 19-item, self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations.17 The 19 items are grouped into 7 components, including (1) sleep duration, (2) sleep disturbance, (3) sleep latency, (4) daytime dysfunction due to sleepiness, (5) sleep efficiency, (6) overall sleep quality, and (7) sleep medication use. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.

  5. Profile of Mood States

    Time frame: 1 month, 2 months, 3 months and at 3 month follow up.

    Profile of Mood States (POMS) score (and subscale scores). The POMS is a 40 item questionnaire assessing mood. The scale is a 5 point scale ranging from "Not at All" (0), "A Little" (1), "Moderately" (2), or "Quite a Lot" (3) or "Extremely" (4). Scores for the seven subscales are calculated by summing the numerical ratings for items that contribute to each subscale. Two of the items on the Esteem-related Affect (ERA) subscale are reverse-scored prior to being combined with the other items. They are all added or subtracted based on the subscale (TMD = [TEN+DEP+ANG+FAT+CON] - [VIG+ERA]. ) to obtain total mood disturbance. A higher score would indicate a negative outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Brianna Krause, MS

CONTACT

[email protected]

‪(513) 400-3057‬

Sponsors and collaborators

Lead sponsor

Ethos Research & Development

Industry

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 8, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.